NAD+ Injections Guard Against Heart Failure in Rats and Beagles

This study evaluated the effect of subcutaneous NAD+ injections in Sprague-Dawley (SD) rats and beagles with heart failure.

Key Points

Subcutaneous injections of NAD+ offered several benefits for animals with heart failure:

  • Heart damage was reduced
  • Functionality of the heart was maintained
  • Blood pressure was improved
  • Scarring of the heart was minimized

Notably, a recent human trial also found that NAD+ injections improved heart function markers following heart failure.

Unlike oral administration, injecting NAD+ bypasses breakdown in the digestive system, potentially yielding different outcomes.

Study Evaluates Effect of NAD+ Injections in Rats and Beagles with Heart Failure

Animals in the heart failure groups underwent surgery to tie off a specific artery, a procedure commonly used to mimic a heart attack.

Sprague-Dawley rats (n=10 per group) and Beagles (n=8 per group) were used in the experiment.

Animals were treated for 4 weeks, starting 1 week after surgery:

  • Sham group: No treatment (healthy control).
  • HF group: No treatment (heart failure).
  • LCZ696 group: Standard heart medication (LCZ696)
  • L-NAD+ group: Low-dose NAD+ injections (rats: 15 mg/kg; beagles: 6 mg/kg)
  • M-NAD+ group: Medium-dose NAD+ injections (rats: 45 mg/kg; beagles:18 mg/kg)
  • H-NAD+ group: High-dose NAD+ injections (rats: 135 mg/kg; beagles: 54 mg/kg)

“The vehicle (Medical grade sterile saline) and NAD+ were administered subcutaneously, while LCZ696 was administered via oral gavage.”

 

Reduced Heart Damage

NAD+ lowered levels of enzymes that indicate heart damage in rats and beagles.

Heart weight was also reduced in rats.

The figure below shows the serum levels of lactic dehydrogenase (LDH), a marker of heart damage, were reduced in beagles.

Beagles receiving medium-dose NAD+ injections (M-NAD+) had significantly reduced levels of LDH compared to the other groups.

Enhanced Heart Function

In rats, all groups receiving NAD+ injection improved measures of heart function, including ejection fraction, stroke volume, and cardiac output.

Beagles also showed improvements in heart function with NAD+ injections:

  • Pumping strength was improved in medium and high dose NAD+ groups
  • Amount of blood pumped per beat was improved in the high dose NAD+ group
  • High dose of NAD+ showed greater improvement in pumping strength than heart medication

The graph below illustrates the percentage of left ventricular ejection fraction (%LVEF) measured in the beagles, which reflects how effectively the heart pumps blood out of the left ventricle.

In beagles with heart failure (HF), the % LVEF was notably lower compared to healthy beagles (Sham). However, in the groups receiving heart medicine (LCZ696) and each dose of NAD+ (L-NAD+, M-NAD+, and H-NAD+), improvements in %LVEF were observed.

Improved Blood Pressure in Rats

Blood pressure and heart pumping pressure was improved in rats receiving medium and high doses of NAD+.

This figure shows systolic blood pressure (SBP) was reduced in rats with heart failure (HF) compared to healthy rats (Sham). Blood pressure was restored in rats that received medium (M-NAD+) and high (H-NAD+) doses of NAD+.

Reduced Heart Scarring

Rats treated with NAD+ injections (medium and high doses) had significantly less scar tissue in their hearts compared to those with untreated heart failure.

In beagles, all doses of NAD+ reduced the extent of damage caused by the heart attack compared to those without NAD+ and those receiving heart medication.

“The therapeutic effects of NAD+ in all NAD+ groups were better than those of LCZ696.”

This figure demonstrates that untreated heart failure in rats (HF) resulted in significant damage compared to healthy rats (Sham). Rats treated with NAD+ at each dose (L-NAD+, M-NAD+, and H-NAD+) showed significantly less damage compared to both the HF group and the group receiving the heart medication (LCZ696).

Conclusion

Treatment with NAD+ injections in rats and beagles with heart failure improved markers of heart function.

“This study, involving rat and beagle MI-induced HF models, indicated that NAD+ significantly improves myocardial hypertrophy and cardiac function, inhibits myocardial fibrosis, and reduces the myocardial infarction rate.”

These findings align with a recent trial indicating that NAD+ injections improved heart function in patients with heart failure.

When taken orally, most of the NAD+ is broken down into nicotinamide (NAM) in the gastrointestinal (GI) tract. However, by administering NAD+ through injections, this breakdown in the gut is bypassed, which may result in different outcomes compared to oral administration.

Dr. Rebecca Crews profile picture

Dr. Rebecca Crews

Learn More

Leading the company’s engagement in transformative research. She is committed to scientific integrity in the health and wellness space and data transparency with consumers.

She holds a Ph.D. in Biochemical and Molecular Nutrition from Tufts University and has over ten years of nutrition science research experience, exploring various dimensions of human well-being in academic and government laboratories.